Literature DB >> 9570447

Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats.

H Hotta1, H Ito, F Kagitani, A Sato.   

Abstract

The effects of cilostazol, a selective cyclic AMP (cAMP) phosphodiesterase inhibitor, on retinal and choroidal blood flow and retinal arteriole diameter were examined in anesthetized rats. The retinal and choroidal blood flow was measured using laser Doppler flowmetry, and the diameter of the retinal arterioles was measured using digital video microscopy. Cilostazol was administered by two routes; systemically via the intravenous route, and directly into the retinal vessels via the intra-arterial route. When administered intravenously, 1 mg/kg of cilostazol produced a biphasic blood flow response, composed of an initial decrease which was dependent on a depressor response of mean arterial pressure, and a subsequent slight but significant increase which was independent of changes in mean arterial pressure. When administered intra-arterially over a 2-min period, 40-55 and 400-440 microg of cilostazol both produced an increase in the blood flow in a dose-dependent manner, while a depressor effect was observed only at the dose of 400-440 microg. The diameter of the retinal arterioles was increased after the intra-arterial injection of cilostazol (400 microg). It is concluded that intra-arterially administered cilostazol induces vasodilation of the retinal arterioles of rats, which results in an increase in blood supply to the retina, independent of changes in mean arterial pressure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570447     DOI: 10.1016/s0014-2999(98)00015-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Viagra-associated serous macular detachment.

Authors:  Polly Quiram; Sean Dumars; Bobbie Parwar; David Sarraf
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-09       Impact factor: 3.117

2.  The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients.

Authors:  Hoon Dong Kim; Si Hyoung Lee; Yoon Kyoung Kim; Jong Rok Oh; Young-Hoon Ohn
Journal:  Doc Ophthalmol       Date:  2016-07-04       Impact factor: 2.379

3.  Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-α-induced nuclear factor-kappa B/activator protein-1 signaling pathway.

Authors:  Fumiya Ishizuka; Masamitsu Shimazawa; Yusuke Egashira; Hiromi Ogishima; Shinsuke Nakamura; Kazuhiro Tsuruma; Hideaki Hara
Journal:  Pharmacol Res Perspect       Date:  2013-10-01

4.  Sildenafil dilates ophthalmic artery in type 2 diabetic patients.

Authors:  Akeel Amh Zwain; Najah R Hadi; Ahmed M Al-Mudhaffer
Journal:  SAGE Open Med       Date:  2013-08-20

5.  Therapeutic Effect of Cilostazol Ophthalmic Nanodispersions on Retinal Dysfunction in Streptozotocin-Induced Diabetic Rats.

Authors:  Noriaki Nagai; Saori Deguchi; Hiroko Otake; Noriko Hiramatsu; Naoki Yamamoto
Journal:  Int J Mol Sci       Date:  2017-09-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.